Brokers Offer Predictions for Genmab A/S FY2025 Earnings

Genmab A/S (NASDAQ:GMAB) – William Blair dropped their FY2025 EPS estimates for Genmab A/S in a report released on Tuesday, January 21st. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of $1.38 for the year, down from their prior forecast of $1.60. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share.

A number of other research firms have also commented on GMAB. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday. Finally, Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Stock Performance

GMAB opened at $20.97 on Thursday. The company has a fifty day moving average price of $21.07 and a two-hundred day moving average price of $23.98. Genmab A/S has a 52 week low of $19.85 and a 52 week high of $31.88. The firm has a market capitalization of $13.88 billion, a PE ratio of 20.36, a P/E/G ratio of 0.59 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the prior year, the business earned $0.47 EPS.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares in the last quarter. R Squared Ltd bought a new stake in Genmab A/S in the 4th quarter valued at $93,000. Blue Trust Inc. lifted its position in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Genmab A/S by 43.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its position in Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.